Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMRN vs FDMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BMRN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

BMRN Overall Winner 6-Pillar Tally: BMRN 5 – 1 FDMT Matrix Metrics: BMRN 8 – 2 FDMT

As of Nov 16, 2026, BioMarin Pharmaceuticals Inc (BMRN) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BMRN carries a Unified Composite Score of 52.6/100 (HOLD) at $58.32 (9.1x Forward P/E, 16.3% operating margin), whereas FDMT carries 51.3/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin).

  • Growth vs. Quality Trade-Off: BMRN earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. FDMT 51.3/100 HOLD) and 0.28β · 31% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BMRN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.0); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMRN vs FDMT
BMRN NASDAQ Head-to-Head Winner
BioMarin Pharmaceuticals Inc
Pharmaceutical Preparations
$58.32
+1.9% 1D
Market Cap $11.0B
TTM Revenue $3.66B
Forward P/E 9.1x
Beta / 30D Vol 0.28β · 31% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 57.0 Fund 61.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.0 · SMA20: $56.73 · SMA50: $58.69
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $12.10 · SMA50: $13.07

6-Pillar Scorecard Institutional Category Breakdown (BMRN 5 – 1 FDMT)

Columns: Metric · BMRN · FDMT
1. Valuation Multiples BMRN
Forward P/E 9.1x N/M
Trailing P/E 8.8x N/M
PEG Ratio 0.34x N/M
EV / Revenue 3.9x 6.6x
2. Growth & Scale FDMT
Revenue Growth (YoY) +32.0% +4505.6%
Earnings Growth (YoY) -81.3% +0.0%
TTM Revenue (USD) $3.66B $96M
Market Cap $11.0B $669.3M
3. Profitability & Quality BMRN
Gross Margin 53.2% N/A
Operating Margin 16.3% -222.7%
Net Profit Margin -0.5% -208.6%
Return on Equity (ROE) -0.3% -56.7%
4. Balance Sheet & Cash Flow BMRN
Cash Generation (TTM) $554M -$156M
Cash Flow Margin 15.2% N/A
Net Cash / Leverage $3.45B Net Debt (0.67x D/E) $31M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BMRN
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 37.4% (17th %ile) 82.4% (10th %ile)
Put/Call OI Skew 0.06x (Call-Skewed) 5.16x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BMRN
OpEx & R&D Intensity 36.9% of Rev ($1.35B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMRN (8) vs FDMT (2)
Institutional Metric BMRN FDMT Criterion Row Edge
Market Capitalization
Scale
$11.0B $669.3M Larger Scale BMRN
Trailing P/E Ratio
Valuation
8.8x N/M Lower Multiple BMRN
Forward P/E Ratio
Valuation
9.1x N/M Lower Multiple BMRN
Revenue Growth (YoY)
Growth
+32.0% +4505.6% Higher Growth FDMT
Operating Margin (TTM)
Profitability
16.3% -222.7% Higher Margin BMRN
Net Profit Margin
Profitability
-0.5% -208.6% Higher Margin BMRN
Return on Equity (ROE)
Capital Efficiency
-0.3% -56.7% Higher ROE BMRN
52-Week Range Position
Momentum
42% ($49–$71) 47% ($7–$17) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
0.28β · 31% Vol 1.89β · 90% Vol Lower Realized Risk BMRN
Unified Institutional Score
Composite Signal
52.6 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite BMRN
Trailing 12M Revenue (USD)
Operating Scale
$3.66B $96M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.34x PEG · 3.9x EV/Rev N/M PEG · 6.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$554M ($3.45B Net Debt (0.67x D/E)) -$156M ($31M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BMRN +10.7 pp
BMRN: +6.66% · FDMT: -4.04%
3M Horizon BMRN +7.92 pp
BMRN: -12.94% · FDMT: -20.86%
6M Horizon FDMT +21.86 pp
BMRN: +17.41% · FDMT: +39.27%
1Y Horizon FDMT +5.77 pp
BMRN: +7.56% · FDMT: +13.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BMRN Revenue FDMT Revenue BMRN Op. Margin FDMT Op. Margin Margin Leader
FY2018 $1.49B N/A -8.3% N/A BMRN
FY2019 $1.70B $10M -5.9% -729.4% BMRN
FY2020 $1.86B $10M -2.3% -424.0% BMRN
FY2021 $1.85B $20M -4.5% -395.5% BMRN
FY2022 $2.10B $0M 7.7% -3516.5% BMRN
FY2023 $2.42B $20M 7.7% -544.6% BMRN
FY2024 $2.85B $0M 17.0% -507678.4% BMRN
FY2025 $3.22B $90M 12.7% -187.2% BMRN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMRN CONSOLIDATION
67d in phase · OBV DISTRIBUTION
Current IV 37.4%
IV Percentile 17th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BMRN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMRN Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $11.0B market capitalization and 16.3% operating margin.
OpEx & R&D Reinvestment 36.9% of Rev ($1.35B)
90D Engineering Disclosures 0 Published
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BMRN vs FDMT Key Questions & Quantitative Answers

As of Nov 16, 2026, BioMarin Pharmaceuticals Inc (BMRN) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BMRN carries a Unified Composite Score of 52.6/100 (HOLD) at $58.32 (9.1x Forward P/E, 16.3% operating margin), whereas FDMT carries 51.3/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin). Growth vs. Quality Trade-Off: BMRN earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. FDMT 51.3/100 HOLD) and 0.28β · 31% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BMRN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.0); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: BMRN posts +32.0% YoY revenue growth and -81.3% YoY earnings growth on $3.66B TTM revenue (53.2% gross margin, 16.3% operating margin), compared with FDMT at +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BMRN cumulative revenue shifted +116.1% while FDMT shifted +800.0%. In operating R&D and SG&A reinvestment, BMRN deploys 36.9% of Rev ($1.35B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FDMT.

BMRN screens cheaper on headline valuation multiples. BMRN trades at 9.1x Forward P/E, 8.8x Trailing P/E, 0.34x PEG, and 3.9x EV/Revenue (15.2% FCF margin), whereas FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRN (-0.3% ROE) versus FDMT (-56.7% ROE) capital efficiency.

In options market volatility and institutional positioning, BMRN carries 37.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.28β · 31% Vol realized risk). By comparison, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.